Literature DB >> 16413592

Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting.

Deborah A Buonagurio1, Robert E O'Neill, Leonid Shutyak, Gail A D'Arco, Thomas M Bechert, Yuriy Kazachkov, Hai-Ping Wang, Joanne DeStefano, Kathleen L Coelingh, Marilyn August, Christopher L Parks, Timothy J Zamb, Mohinder S Sidhu, Stephen A Udem.   

Abstract

The genetic and phenotypic stability of viruses isolated from young children following intranasal administration of the trivalent live-attenuated influenza virus vaccine (LAIV, marketed in the United States as FluMist) was evaluated by determination of genomic sequence and assessment of the cold-adapted (ca), temperature-sensitive (ts) and attenuated (att) phenotypes. The complete genomic sequence was determined for 56 independent isolates obtained from children following vaccination (21 type A/H1N1, 12 A/H3N2, 1 A/H3N1 and 22 type B viruses), 20% of which had no nucleotide misincorporations compared with administered vaccine. The remaining isolates had from one to seven changes per genome. None of the observed misincorporations resulted in predicted amino acid codon substitutions at sites previously shown to contribute to the ca, ts or att phenotypes, and all vaccine-derived isolates retained ca and ts phenotypes consistent with the observation that none of the vaccine recipients displayed distinctive symptoms. The results indicate that LAIV strains undergo very limited genetic change following replication in vaccine recipients and that those changes did not affect vaccine attenuation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16413592     DOI: 10.1016/j.virol.2005.11.006

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

2.  Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines.

Authors:  Sanae Sasaki; Maria C Jaimes; Tyson H Holmes; Cornelia L Dekker; Kutubuddin Mahmood; George W Kemble; Ann M Arvin; Harry B Greenberg
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

3.  Recommendations on the use of live, attenuated influenza vaccine (FluMist®): Supplemental Statement on Seasonal Influenza Vaccine for 2011-2012 An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2011-11-30

4.  Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus.

Authors:  Bin Zhou; Victoria A Meliopoulos; Wei Wang; Xudong Lin; Karla M Stucker; Rebecca A Halpin; Timothy B Stockwell; Stacey Schultz-Cherry; David E Wentworth
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

5.  Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine.

Authors:  Amy L Vincent; Wenjun Ma; Kelly M Lager; Bruce H Janke; Richard J Webby; Adolfo García-Sastre; Jürgen A Richt
Journal:  Vaccine       Date:  2007-09-29       Impact factor: 3.641

6.  Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice.

Authors:  Hae-Jung Park; Boris Ferko; Young-Ho Byun; Joo-Hye Song; Gye-Yeong Han; Elisabeth Roethl; Andrej Egorov; Thomas Muster; Baiklin Seong; Mi-Na Kweon; Manki Song; Cecil Czerkinsky; Huan H Nguyen
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

7.  How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines.

Authors:  Rajeev Rudraraju; Francesca Mordant; Kanta Subbarao
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.